Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACAD NASDAQ:CRNX NASDAQ:SANA NASDAQ:VKTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACADACADIA Pharmaceuticals$25.77-0.8%$22.26$19.69▼$28.35$4.45B0.81.62 million shs1.15 million shsCRNXCrinetics Pharmaceuticals$42.03-0.5%$36.77$25.83▼$57.99$4.45B0.231.24 million shs5.37 million shsSANASana Biotechnology$3.97-1.0%$3.22$2.61▼$6.55$1.12B2.133.68 million shs3.41 million shsVKTXViking Therapeutics$38.71+3.4%$32.04$22.96▼$43.15$4.35B0.662.68 million shs2.12 million shsDon't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACADACADIA Pharmaceuticals-0.77%+2.26%+19.53%+16.66%+23.01%CRNXCrinetics Pharmaceuticals-0.47%+13.78%+27.67%+9.42%+40.69%SANASana Biotechnology-1.00%+15.07%+48.13%+26.03%+24.26%VKTXViking Therapeutics+3.39%-2.10%+36.06%+14.87%+37.46%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACADACADIA Pharmaceuticals$25.77-0.8%$22.26$19.69▼$28.35$4.45B0.81.62 million shs1.15 million shsCRNXCrinetics Pharmaceuticals$42.03-0.5%$36.77$25.83▼$57.99$4.45B0.231.24 million shs5.37 million shsSANASana Biotechnology$3.97-1.0%$3.22$2.61▼$6.55$1.12B2.133.68 million shs3.41 million shsVKTXViking Therapeutics$38.71+3.4%$32.04$22.96▼$43.15$4.35B0.662.68 million shs2.12 million shsDon't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACADACADIA Pharmaceuticals-0.77%+2.26%+19.53%+16.66%+23.01%CRNXCrinetics Pharmaceuticals-0.47%+13.78%+27.67%+9.42%+40.69%SANASana Biotechnology-1.00%+15.07%+48.13%+26.03%+24.26%VKTXViking Therapeutics+3.39%-2.10%+36.06%+14.87%+37.46%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACADACADIA Pharmaceuticals 2.65Moderate Buy$32.5926.46% UpsideCRNXCrinetics Pharmaceuticals 2.91Moderate Buy$73.7875.54% UpsideSANASana Biotechnology 2.67Moderate Buy$9.50139.29% UpsideVKTXViking Therapeutics 2.79Moderate Buy$93.60141.80% UpsideCurrent Analyst Ratings BreakdownLatest SANA, CRNX, ACAD, and VKTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/2/2026CRNXCrinetics Pharmaceuticals UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$55.006/30/2026ACADACADIA Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold6/30/2026ACADACADIA Pharmaceuticals Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$29.00 ➝ $30.006/29/2026ACADACADIA Pharmaceuticals Deutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$37.006/29/2026ACADACADIA Pharmaceuticals CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$32.00 ➝ $35.006/29/2026ACADACADIA Pharmaceuticals Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$32.00 ➝ $36.006/15/2026CRNXCrinetics Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$81.006/11/2026CRNXCrinetics Pharmaceuticals Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform$95.005/28/2026VKTXViking Therapeutics Lake Street CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$89.005/27/2026VKTXViking Therapeutics Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$83.005/11/2026CRNXCrinetics Pharmaceuticals OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$87.00 ➝ $84.00(Data available from 7/7/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACADACADIA Pharmaceuticals$1.07B4.12$0.88 per share29.27$7.25 per share3.55CRNXCrinetics Pharmaceuticals$7.70M575.54N/AN/A$9.71 per share4.33SANASana BiotechnologyN/AN/AN/AN/A$0.60 per shareN/AVKTXViking TherapeuticsN/AN/AN/AN/A$5.65 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACADACADIA Pharmaceuticals$391M$2.2011.7129.9718.7134.30%9.61%7.07%8/5/2026 (Estimated)CRNXCrinetics Pharmaceuticals-$465.32M-$5.13N/AN/AN/A-2,747.18%-43.96%-39.61%8/4/2026 (Estimated)SANASana Biotechnology-$244.17M-$0.93N/AN/AN/AN/A-108.01%-40.68%8/10/2026 (Estimated)VKTXViking Therapeutics-$359.64M-$4.14N/AN/AN/AN/A-71.31%-65.35%7/29/2026 (Estimated)Latest SANA, CRNX, ACAD, and VKTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails7/29/2026Q2 2026VKTXViking Therapeutics-$1.21N/AN/AN/AN/AN/A5/11/2026Q1 2026SANASana Biotechnology-$0.15-$0.14+$0.01-$0.17N/AN/A5/7/2026Q1 2026CRNXCrinetics Pharmaceuticals-$1.22-$1.23-$0.01-$1.23$8.51 million$10.73 million5/6/2026Q1 2026ACADACADIA Pharmaceuticals$0.04$0.02-$0.02$0.02$280.25 million$268.10 million4/30/2026Q1 2026VKTXViking Therapeutics-$1.01-$1.37-$0.36-$1.37N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthACADACADIA PharmaceuticalsN/AN/AN/AN/AN/ACRNXCrinetics PharmaceuticalsN/AN/AN/AN/AN/ASANASana BiotechnologyN/AN/AN/AN/AN/AVKTXViking TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACADACADIA PharmaceuticalsN/A3.593.48CRNXCrinetics PharmaceuticalsN/A18.6018.56SANASana BiotechnologyN/A1.291.29VKTXViking TherapeuticsN/A5.725.72Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACADACADIA Pharmaceuticals96.71%CRNXCrinetics Pharmaceuticals98.51%SANASana Biotechnology88.23%VKTXViking Therapeutics76.03%Insider OwnershipCompanyInsider OwnershipACADACADIA Pharmaceuticals26.20%CRNXCrinetics Pharmaceuticals3.80%SANASana Biotechnology25.40%VKTXViking Therapeutics5.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACADACADIA Pharmaceuticals510171.24 million126.37 millionOptionableCRNXCrinetics Pharmaceuticals210105.44 million101.43 millionOptionableSANASana Biotechnology380278.29 million207.61 millionOptionableVKTXViking Therapeutics20116.11 million109.95 millionOptionableSANA, CRNX, ACAD, and VKTX HeadlinesRecent News About These CompaniesHow Much Could $1,000 Invested in Viking Therapeutics Be Worth by 2030?July 5 at 1:05 AM | fool.comIs Viking Therapeutics Stock Going to $50? Here's What the Bulls and Bears Are SayingJuly 4 at 5:10 AM | fool.comHere's Why Viking Therapeutics Stock Surged Higher in JuneJuly 3, 2026 | fool.comCantor Fitzgerald Remains a Buy on Viking Therapeutics (VKTX)July 3, 2026 | theglobeandmail.comViking Therapeutics, Inc. (VKTX) Sees a More Significant Dip Than Broader Market: Some Facts to KnowJuly 1, 2026 | finance.yahoo.comViking Therapeutics, Inc. (VKTX) Sees a More Significant Dip Than Broader Market: Some Facts to KnowJuly 1, 2026 | zacks.comIs Viking Therapeutics Stock Going to $100?July 1, 2026 | fool.comNovo Nordisk vs. Viking: Which Obesity Drug Stock Is the Better Buy?June 29, 2026 | zacks.comIs It Worth Investing in Viking Therapeutics (VKTX) Based on Wall Street's Bullish Views?June 29, 2026 | finance.yahoo.comIs It Worth Investing in Viking Therapeutics (VKTX) Based on Wall Street's Bullish Views?June 29, 2026 | zacks.comAnalysts Offer Insights on Healthcare Companies: Neurosense Therapeutics Ltd. (NRSN) and Viking Therapeutics (VKTX)June 26, 2026 | theglobeandmail.comDyne Therapeutics vs. Viking Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?June 26, 2026 | fool.comViking Therapeutics, Inc. (VKTX) Sees a More Significant Dip Than Broader Market: Some Facts to KnowJune 25, 2026 | finance.yahoo.comViking Therapeutics (VKTX) Starts First Human Obesity Trial For VK3019June 25, 2026 | finance.yahoo.comViking Therapeutics, Inc. (VKTX) Sees a More Significant Dip Than Broader Market: Some Facts to KnowJune 25, 2026 | zacks.comVKTX Stock Jumps on Phase I Study Initiation for New Obesity DrugJune 25, 2026 | finance.yahoo.comVKTX Stock Jumps on Phase I Study Initiation for New Obesity DrugJune 25, 2026 | zacks.comVKTX Stock On Track For Five Consecutive Days Of Gains — Viking Launches Human Trial For Novel Obesity Drug VK3019June 24, 2026 | stocktwits.comSViking Therapeutics Announces Initiation of Phase 1 Study to Evaluate Novel Amylin Receptor Agonist VK3019 in Healthy AdultsJune 24, 2026 | finance.yahoo.comViking Therapeutics Announces Initiation of Phase 1 Study to Evaluate Novel Amylin Receptor Agonist VK3019 in Healthy AdultsJune 24, 2026 | prnewswire.comViking Therapeutics Faces Timeline Risk—But Upside Could Be Huge...May 1, 2026 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSANA, CRNX, ACAD, and VKTX Company DescriptionsACADIA Pharmaceuticals NASDAQ:ACAD$25.77 -0.20 (-0.77%) Closing price 07/6/2026 04:00 PM EasternExtended Trading$25.35 -0.42 (-1.63%) As of 07/6/2026 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.Crinetics Pharmaceuticals NASDAQ:CRNX$42.03 -0.20 (-0.47%) Closing price 07/6/2026 04:00 PM EasternExtended Trading$84.05 +42.02 (+99.98%) As of 07/6/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.Sana Biotechnology NASDAQ:SANA$3.97 -0.04 (-1.00%) Closing price 07/6/2026 04:00 PM EasternExtended Trading$3.90 -0.07 (-1.86%) As of 07/6/2026 07:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company's product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin's lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others. It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.Viking Therapeutics NASDAQ:VKTX$38.71 +1.27 (+3.39%) Closing price 07/6/2026 04:00 PM EasternExtended Trading$38.44 -0.27 (-0.71%) As of 07/6/2026 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Flash Crash or Cash? The AI Hardware Reset Investors Can’t Ignore KBR Insiders Are Buying While the Market Misreads Its Spinoff Doug Casey Calls AI a Super Bubble, Bets on Energy, Gold Miners and Grains Contrarian Alert: 5 Downgraded Stocks That May Reward Long-Term Investors This Edge AI Stock Just Got a Huge Vote of Confidence From Wall Street AI Is Selling Off, But These 5 Stocks Could Benefit Next MarketBeat Week in Review – 06/29 - 07/03 Analysts Just Raised Price Targets On These 3 Semiconductor Equipment Stocks Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
